[go: up one dir, main page]

NO20053356L - Aminindazolderivater og anvendelse derav som kinaseinhibitorer. - Google Patents

Aminindazolderivater og anvendelse derav som kinaseinhibitorer.

Info

Publication number
NO20053356L
NO20053356L NO20053356A NO20053356A NO20053356L NO 20053356 L NO20053356 L NO 20053356L NO 20053356 A NO20053356 A NO 20053356A NO 20053356 A NO20053356 A NO 20053356A NO 20053356 L NO20053356 L NO 20053356L
Authority
NO
Norway
Prior art keywords
aminindazole
derivatives
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
NO20053356A
Other languages
English (en)
Other versions
NO20053356D0 (no
NO330835B1 (no
Inventor
Gilles Dutruc-Rosset
Didier Babin
Frank Halley
Gilles Tiraboschi
Dominique Le Suisse
Thomas Rooney
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0215720A external-priority patent/FR2848554A1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20053356D0 publication Critical patent/NO20053356D0/no
Publication of NO20053356L publication Critical patent/NO20053356L/no
Publication of NO330835B1 publication Critical patent/NO330835B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20053356A 2002-12-12 2005-07-11 Aminindazolderivater, fremgangsmate for fremstilling derav, mellomprodukt samt farmasoytisk preparat inneholdende et slikt derivat NO330835B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0215720A FR2848554A1 (fr) 2002-12-12 2002-12-12 Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US44463003P 2003-02-04 2003-02-04
PCT/FR2003/002634 WO2004062662A1 (fr) 2002-12-12 2003-09-03 Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases

Publications (3)

Publication Number Publication Date
NO20053356D0 NO20053356D0 (no) 2005-07-11
NO20053356L true NO20053356L (no) 2005-07-11
NO330835B1 NO330835B1 (no) 2011-07-25

Family

ID=32715101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053356A NO330835B1 (no) 2002-12-12 2005-07-11 Aminindazolderivater, fremgangsmate for fremstilling derav, mellomprodukt samt farmasoytisk preparat inneholdende et slikt derivat

Country Status (13)

Country Link
US (4) US7019011B2 (no)
EP (1) EP1572200B1 (no)
KR (1) KR20050084271A (no)
BR (1) BR0316606A (no)
CA (1) CA2507948A1 (no)
HR (1) HRP20050533A2 (no)
MA (1) MA27561A1 (no)
MX (1) MXPA05005554A (no)
NO (1) NO330835B1 (no)
NZ (1) NZ541193A (no)
PL (1) PL376789A1 (no)
RU (1) RU2339624C2 (no)
WO (1) WO2004062662A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL376789A1 (pl) * 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
WO2007075847A2 (en) * 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
DE102006005180A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006033140A1 (de) * 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) * 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
TW201041879A (en) 2009-02-26 2010-12-01 Glaxo Group Ltd Novel compounds
BR112012020271A2 (pt) 2010-02-11 2017-08-29 Univ Vanderbilt Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica
TWI476188B (zh) 2010-05-27 2015-03-11 Ube Industries 新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US10085979B2 (en) 2014-12-02 2018-10-02 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
CN107735401B (zh) 2015-06-15 2021-08-31 宇部兴产株式会社 取代二氢吡咯并吡唑衍生物
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN110167554B (zh) * 2016-11-17 2023-05-23 思路迪（北京）医药科技有限公司 一种具有抗癌作用的化合物及其制备方法和应用
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
WO2020010092A1 (en) 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230002320A1 (en) * 2019-10-03 2023-01-05 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
CN115260165B (zh) * 2021-04-29 2024-08-06 中国科学院上海药物研究所 苯并含氮五元杂环化合物及其合成和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
AU2001277752A1 (en) * 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE10106147A1 (de) * 2001-02-10 2002-08-14 Clariant Gmbh Saure Pigmentdispergatoren und Pigmentzubereitungen
DE60132662T2 (de) * 2001-07-03 2009-02-05 Barco N.V. Verfahren und Einrichtung zur Echtzeitkorrektur eines Bildes
DE60238999D1 (de) 2001-09-26 2011-03-03 Pfizer Italia Srl Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003278249B8 (en) 2002-09-05 2010-11-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
PL376789A1 (pl) * 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy

Also Published As

Publication number Publication date
US7019011B2 (en) 2006-03-28
CA2507948A1 (fr) 2004-07-29
NO20053356D0 (no) 2005-07-11
PL376789A1 (pl) 2006-01-09
KR20050084271A (ko) 2005-08-26
US20040132794A1 (en) 2004-07-08
BR0316606A (pt) 2005-10-11
WO2004062662A1 (fr) 2004-07-29
AU2003278250A1 (en) 2004-08-10
US20070155735A1 (en) 2007-07-05
RU2339624C2 (ru) 2008-11-27
EP1572200B1 (fr) 2011-08-17
US20080261997A1 (en) 2008-10-23
US7407981B2 (en) 2008-08-05
HRP20050533A2 (en) 2006-11-30
US20060074122A1 (en) 2006-04-06
NZ541193A (en) 2009-01-31
US7196109B2 (en) 2007-03-27
MA27561A1 (fr) 2005-10-03
MXPA05005554A (es) 2005-07-26
EP1572200A1 (fr) 2005-09-14
US7629374B2 (en) 2009-12-08
RU2005121897A (ru) 2006-01-20
NO330835B1 (no) 2011-07-25

Similar Documents

Publication Publication Date Title
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
NO20053215D0 (no) Pyrazolderivater med anvendelse som COX-1-inhibitorer.
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
IS7599A (is) Heterósýklískir kínasatálmar
DK1997810T3 (da) Indazoler, benzotriazoler og N-analoger deraf som p38-kinaseinhibitorer
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20044062L (no) N-aryl-2-oksazolidinon-5-karboksamider og deres derivater og deres anvendelse som antibakterielle midler
NO20032830L (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celleproliferasjonsinhibitorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees